APO Research
Talk to an analyst

APO RESEARCH · REPORT

Analgesic and Anti-inflammatory API

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Analgesic and Anti-inflammatory API Market Outlook and Growth Opportunities 2026

1 February 2026196 pages

Choose your research edition.

Industry ResearchAnalgesic and Anti-inflammatory API Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Analgesic and Anti-inflammatory API Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Analgesic and Anti-inflammatory API Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Analgesic and Anti-inflammatory API Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Analgesic and Anti-inflammatory API Market Analysis and Forecast 2026-2032213 pages · $4,950 USD

Market perspective

The global Analgesic and Anti-inflammatory API market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Analgesic and Anti-inflammatory API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Analgesic and Anti-inflammatory API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Analgesic and Anti-inflammatory API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Analgesic and Anti-inflammatory API market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Analgesic and Anti-inflammatory API market include IOL, Granules India Limited, Mallinckrodt Pharmaceuticals, Novacyl, BASF, Hubei Biocause Group, BBCA Group, Hebei Jiheng Pharmaceutical and Hunan Zhongnan Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Analgesic and Anti-inflammatory API market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Analgesic and Anti-inflammatory API and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Analgesic and Anti-inflammatory API sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Analgesic and Anti-inflammatory API market size, projected growth trends, production technologies, key applications, and end-use industries.

Analgesic and Anti-inflammatory API Segment by Company

IOL

Granules India Limited

Mallinckrodt Pharmaceuticals

Novacyl

BASF

Hubei Biocause Group

BBCA Group

Hebei Jiheng Pharmaceutical

Hunan Zhongnan Pharmaceutical

Hebei Jingye Medical Technology

Anqiu Lu'an Pharmaceutical

Xinhua Pharm

Zhejiang Kangle Pharmaceutical

Analgesic and Anti-inflammatory API Segment by Type

Dexibuprofen

Diclofenac

Paracetamol

Naproxen

Ibuprofen

Oxaprozin

Aspirin

Others

Analgesic and Anti-inflammatory API Segment by Application

Adults

Children

Analgesic and Anti-inflammatory API Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Analgesic and Anti-inflammatory API status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Analgesic and Anti-inflammatory API market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Analgesic and Anti-inflammatory API significant trends, drivers, influence factors in global and regions.

6. To analyze Analgesic and Anti-inflammatory API competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Analgesic and Anti-inflammatory API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Analgesic and Anti-inflammatory API and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Analgesic and Anti-inflammatory API.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Analgesic and Anti-inflammatory API market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Analgesic and Anti-inflammatory API industry.

Chapter 3: Detailed analysis of Analgesic and Anti-inflammatory API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Analgesic and Anti-inflammatory API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Analgesic and Anti-inflammatory API in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Analgesic and Anti-inflammatory API Industry Trends Table 2. Analgesic and Anti-inflammatory API Industry Drivers Table 3. Analgesic and Anti-inflammatory API Industry Opportunities and Challenges Table 4. Analgesic and Anti-inflammatory API Industry Restraints Table 5. Global Analgesic and Anti-inflammatory API Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Analgesic and Anti-inflammatory API Revenue Share by Company (2021-2026) Table 7. Global Analgesic and Anti-inflammatory API Sales Volume by Company (t) & (2021-2026) Table 8. Global Analgesic and Anti-inflammatory API Sales Volume Share by Company (2021-2026) Table 9. Global Analgesic and Anti-inflammatory API Average Price (USD/t) of Company (2021-2026) Table 10. Global Analgesic and Anti-inflammatory API Company Ranking, (2024-2026) & (USD Million) Table 11. Global Analgesic and Anti-inflammatory API Key Company Manufacturing Base & Headquarters Table 12. Global Analgesic and Anti-inflammatory API Company, Product Type & Application Table 13. Global Analgesic and Anti-inflammatory API Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Analgesic and Anti-inflammatory API by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Dexibuprofen Table 18. Significant Companies of Diclofenac Table 19. Significant Companies of Paracetamol Table 20. Significant Companies of Naproxen Table 21. Significant Companies of Ibuprofen Table 22. Significant Companies of Oxaprozin Table 23. Significant Companies of Aspirin Table 24. Significant Companies of Others Table 25. Global Analgesic and Anti-inflammatory API Sales Volume by Type 2021 VS 2025 VS 2032 (t) Table 26. Global Analgesic and Anti-inflammatory API Sales Volume by Type (2021-2026) & (t) Table 27. Global Analgesic and Anti-inflammatory API Sales Volume by Type (2027-2032) & (t) Table 28. Global Analgesic and Anti-inflammatory API Sales Volume Share by Type (2021-2026) Table 29. Global Analgesic and Anti-inflammatory API Sales Volume Share by Type (2027-2032) Table 30. Global Analgesic and Anti-inflammatory API Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Analgesic and Anti-inflammatory API Sales Value by Type (2021-2026) & (US$ Million) Table 32. Global Analgesic and Anti-inflammatory API Sales Value by Type (2027-2032) & (US$ Million) Table 33. Global Analgesic and Anti-inflammatory API Sales Value Share by Type (2021-2026) Table 34. Global Analgesic and Anti-inflammatory API Sales Value Share by Type (2027-2032) Table 35. Significant Companies of Adults Table 36. Significant Companies of Children Table 37. Global Analgesic and Anti-inflammatory API Sales Volume by Application 2021 VS 2025 VS 2032 (t) Table 38. Global Analgesic and Anti-inflammatory API Sales Volume by Application (2021-2026) & (t) Table 39. Global Analgesic and Anti-inflammatory API Sales Volume by Application (2027-2032) & (t) Table 40. Global Analgesic and Anti-inflammatory API Sales Volume Share by Application (2021-2026) Table 41. Global Analgesic and Anti-inflammatory API Sales Volume Share by Application (2027-2032) Table 42. Global Analgesic and Anti-inflammatory API Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Analgesic and Anti-inflammatory API Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Analgesic and Anti-inflammatory API Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Analgesic and Anti-inflammatory API Sales Value Share by Application (2021-2026) Table 46. Global Analgesic and Anti-inflammatory API Sales Value Share by Application (2027-2032) Table 47. Global Analgesic and Anti-inflammatory API Sales by Region: 2021 VS 2025 VS 2032 (t) Table 48. Global Analgesic and Anti-inflammatory API Sales by Region (2021-2026) & (t) Table 49. Global Analgesic and Anti-inflammatory API Sales Market Share by Region (2021-2026) Table 50. Global Analgesic and Anti-inflammatory API Sales by Region (2027-2032) & (t) Table 51. Global Analgesic and Anti-inflammatory API Sales Market Share by Region (2027-2032) Table 52. Global Analgesic and Anti-inflammatory API Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Analgesic and Anti-inflammatory API Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Analgesic and Anti-inflammatory API Sales Value Share by Region (2021-2026) Table 55. Global Analgesic and Anti-inflammatory API Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Analgesic and Anti-inflammatory API Sales Value Share by Region (2027-2032) Table 57. Global Analgesic and Anti-inflammatory API Market Average Price (USD/t) by Region (2021-2026) Table 58. Global Analgesic and Anti-inflammatory API Market Average Price (USD/t) by Region (2027-2032) Table 59. Global Analgesic and Anti-inflammatory API Sales by Country: 2021 VS 2025 VS 2032 (t) Table 60. Global Analgesic and Anti-inflammatory API Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Analgesic and Anti-inflammatory API Sales by Country (2021-2026) & (t) Table 62. Global Analgesic and Anti-inflammatory API Sales Market Share by Country (2021-2026) Table 63. Global Analgesic and Anti-inflammatory API Sales by Country (2027-2032) & (t) Table 64. Global Analgesic and Anti-inflammatory API Sales Market Share by Country (2027-2032) Table 65. Global Analgesic and Anti-inflammatory API Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Analgesic and Anti-inflammatory API Sales Value Market Share by Country (2021-2026) Table 67. Global Analgesic and Anti-inflammatory API Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Analgesic and Anti-inflammatory API Sales Value Market Share by Country (2027-2032) Table 69. IOL Company Information Table 70. IOL Business Overview Table 71. IOL Analgesic and Anti-inflammatory API Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 72. IOL Analgesic and Anti-inflammatory API Product Portfolio Table 73. IOL Recent Development Table 74. Granules India Limited Company Information Table 75. Granules India Limited Business Overview Table 76. Granules India Limited Analgesic and Anti-inflammatory API Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 77. Granules India Limited Analgesic and Anti-inflammatory API Product Portfolio Table 78. Granules India Limited Recent Development Table 79. Mallinckrodt Pharmaceuticals Company Information Table 80. Mallinckrodt Pharmaceuticals Business Overview Table 81. Mallinckrodt Pharmaceuticals Analgesic and Anti-inflammatory API Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 82. Mallinckrodt Pharmaceuticals Analgesic and Anti-inflammatory API Product Portfolio Table 83. Mallinckrodt Pharmaceuticals Recent Development Table 84. Novacyl Company Information Table 85. Novacyl Business Overview Table 86. Novacyl Analgesic and Anti-inflammatory API Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 87. Novacyl Analgesic and Anti-inflammatory API Product Portfolio Table 88. Novacyl Recent Development Table 89. BASF Company Information Table 90. BASF Business Overview Table 91. BASF Analgesic and Anti-inflammatory API Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 92. BASF Analgesic and Anti-inflammatory API Product Portfolio Table 93. BASF Recent Development Table 94. Hubei Biocause Group Company Information Table 95. Hubei Biocause Group Business Overview Table 96. Hubei Biocause Group Analgesic and Anti-inflammatory API Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 97. Hubei Biocause Group Analgesic and Anti-inflammatory API Product Portfolio Table 98. Hubei Biocause Group Recent Development Table 99. BBCA Group Company Information Table 100. BBCA Group Business Overview Table 101. BBCA Group Analgesic and Anti-inflammatory API Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 102. BBCA Group Analgesic and Anti-inflammatory API Product Portfolio Table 103. BBCA Group Recent Development Table 104. Hebei Jiheng Pharmaceutical Company Information Table 105. Hebei Jiheng Pharmaceutical Business Overview Table 106. Hebei Jiheng Pharmaceutical Analgesic and Anti-inflammatory API Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 107. Hebei Jiheng Pharmaceutical Analgesic and Anti-inflammatory API Product Portfolio Table 108. Hebei Jiheng Pharmaceutical Recent Development Table 109. Hunan Zhongnan Pharmaceutical Company Information Table 110. Hunan Zhongnan Pharmaceutical Business Overview Table 111. Hunan Zhongnan Pharmaceutical Analgesic and Anti-inflammatory API Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 112. Hunan Zhongnan Pharmaceutical Analgesic and Anti-inflammatory API Product Portfolio Table 113. Hunan Zhongnan Pharmaceutical Recent Development Table 114. Hebei Jingye Medical Technology Company Information Table 115. Hebei Jingye Medical Technology Business Overview Table 116. Hebei Jingye Medical Technology Analgesic and Anti-inflammatory API Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 117. Hebei Jingye Medical Technology Analgesic and Anti-inflammatory API Product Portfolio Table 118. Hebei Jingye Medical Technology Recent Development Table 119. Anqiu Lu'an Pharmaceutical Company Information Table 120. Anqiu Lu'an Pharmaceutical Business Overview Table 121. Anqiu Lu'an Pharmaceutical Analgesic and Anti-inflammatory API Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 122. Anqiu Lu'an Pharmaceutical Analgesic and Anti-inflammatory API Product Portfolio Table 123. Anqiu Lu'an Pharmaceutical Recent Development Table 124. Xinhua Pharm Company Information Table 125. Xinhua Pharm Business Overview Table 126. Xinhua Pharm Analgesic and Anti-inflammatory API Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 127. Xinhua Pharm Analgesic and Anti-inflammatory API Product Portfolio Table 128. Xinhua Pharm Recent Development Table 129. Zhejiang Kangle Pharmaceutical Company Information Table 130. Zhejiang Kangle Pharmaceutical Business Overview Table 131. Zhejiang Kangle Pharmaceutical Analgesic and Anti-inflammatory API Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 132. Zhejiang Kangle Pharmaceutical Analgesic and Anti-inflammatory API Product Portfolio Table 133. Zhejiang Kangle Pharmaceutical Recent Development Table 134. Key Raw Materials Table 135. Raw Materials Key Suppliers Table 136. Analgesic and Anti-inflammatory API Distributors List Table 137. Analgesic and Anti-inflammatory API Customers List Table 138. Research Programs/Design for This Report Table 139. Authors List of This Report Table 140. Secondary Sources Table 141. Primary Sources List of Figures Figure 1. Analgesic and Anti-inflammatory API Product Image Figure 2. Global Analgesic and Anti-inflammatory API Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Analgesic and Anti-inflammatory API Sales Value (2021-2032) & (US$ Million) Figure 4. Global Analgesic and Anti-inflammatory API Sales (2021-2032) & (t) Figure 5. Global Analgesic and Anti-inflammatory API Sales Average Price (USD/t) & (2021-2032) Figure 6. Global Analgesic and Anti-inflammatory API Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Dexibuprofen Image Figure 10. Diclofenac Image Figure 11. Paracetamol Image Figure 12. Naproxen Image Figure 13. Ibuprofen Image Figure 14. Oxaprozin Image Figure 15. Aspirin Image Figure 16. Others Image Figure 17. Global Analgesic and Anti-inflammatory API Sales Volume by Type (2021 VS 2025 VS 2032) & (t) Figure 18. Global Analgesic and Anti-inflammatory API Sales Volume Share 2021 VS 2025 VS 2032 Figure 19. Global Analgesic and Anti-inflammatory API Sales Volume Share by Type (2021-2032) Figure 20. Global Analgesic and Anti-inflammatory API Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Analgesic and Anti-inflammatory API Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Analgesic and Anti-inflammatory API Sales Value Share by Type (2021-2032) Figure 23. Adults Image Figure 24. Children Image Figure 25. Global Analgesic and Anti-inflammatory API Sales Volume by Application (2021 VS 2025 VS 2032) & (t) Figure 26. Global Analgesic and Anti-inflammatory API Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Analgesic and Anti-inflammatory API Sales Volume Share by Application (2021-2032) Figure 28. Global Analgesic and Anti-inflammatory API Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Analgesic and Anti-inflammatory API Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Analgesic and Anti-inflammatory API Sales Value Share by Application (2021-2032) Figure 31. Global Analgesic and Anti-inflammatory API Sales by Region: 2021 VS 2025 VS 2032 (t) Figure 32. Global Analgesic and Anti-inflammatory API Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Analgesic and Anti-inflammatory API Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Analgesic and Anti-inflammatory API Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Analgesic and Anti-inflammatory API Sales Value (2021-2032) & (US$ Million) Figure 36. North America Analgesic and Anti-inflammatory API Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Analgesic and Anti-inflammatory API Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Analgesic and Anti-inflammatory API Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Analgesic and Anti-inflammatory API Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Analgesic and Anti-inflammatory API Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Analgesic and Anti-inflammatory API Sales Value (2021-2032) & (US$ Million) Figure 42. South America Analgesic and Anti-inflammatory API Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Analgesic and Anti-inflammatory API Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Analgesic and Anti-inflammatory API Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Analgesic and Anti-inflammatory API Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Analgesic and Anti-inflammatory API Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • Dexibuprofen
  • Diclofenac
  • Paracetamol
  • Naproxen
  • Ibuprofen
  • Oxaprozin
  • Aspirin
  • Others
Applications
  • Adults
  • Children
Companies covered
  • IOL
  • Granules India Limited
  • Mallinckrodt Pharmaceuticals
  • Novacyl
  • BASF
  • Hubei Biocause Group
  • BBCA Group
  • Hebei Jiheng Pharmaceutical
  • Hunan Zhongnan Pharmaceutical
  • Hebei Jingye Medical Technology
  • Anqiu Lu'an Pharmaceutical
  • Xinhua Pharm
  • Zhejiang Kangle Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Analgesic and Anti-inflammatory API Sales Value (2021-2032)
  4. 1.2.2 Global Analgesic and Anti-inflammatory API Sales Volume (2021-2032)
  5. 1.2.3 Global Analgesic and Anti-inflammatory API Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Analgesic and Anti-inflammatory API Market Dynamics
  1. 2.1 Analgesic and Anti-inflammatory API Industry Trends
  2. 2.2 Analgesic and Anti-inflammatory API Industry Drivers
  3. 2.3 Analgesic and Anti-inflammatory API Industry Opportunities and Challenges
  4. 2.4 Analgesic and Anti-inflammatory API Industry Restraints
3 Analgesic and Anti-inflammatory API Market by Company
  1. 3.1 Global Analgesic and Anti-inflammatory API Company Revenue Ranking in 2025
  2. 3.2 Global Analgesic and Anti-inflammatory API Revenue by Company (2021-2026)
  3. 3.3 Global Analgesic and Anti-inflammatory API Sales Volume by Company (2021-2026)
  4. 3.4 Global Analgesic and Anti-inflammatory API Average Price by Company (2021-2026)
  5. 3.5 Global Analgesic and Anti-inflammatory API Company Ranking (2024-2026)
  6. 3.6 Global Analgesic and Anti-inflammatory API Company Manufacturing Base and Headquarters
  7. 3.7 Global Analgesic and Anti-inflammatory API Company Product Type and Application
  8. 3.8 Global Analgesic and Anti-inflammatory API Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Analgesic and Anti-inflammatory API Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Analgesic and Anti-inflammatory API Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Analgesic and Anti-inflammatory API Market by Type
  1. 4.1 Analgesic and Anti-inflammatory API Type Introduction
  2. 4.1.1 Dexibuprofen
  3. 4.1.2 Diclofenac
  4. 4.1.3 Paracetamol
  5. 4.1.4 Naproxen
  6. 4.1.5 Ibuprofen
  7. 4.1.6 Oxaprozin
  8. 4.1.7 Aspirin
  9. 4.1.8 Others
  10. 4.2 Global Analgesic and Anti-inflammatory API Sales Volume by Type
  11. 4.2.1 Global Analgesic and Anti-inflammatory API Sales Volume by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Analgesic and Anti-inflammatory API Sales Volume by Type (2021-2032)
  13. 4.2.3 Global Analgesic and Anti-inflammatory API Sales Volume Share by Type (2021-2032)
  14. 4.3 Global Analgesic and Anti-inflammatory API Sales Value by Type
  15. 4.3.1 Global Analgesic and Anti-inflammatory API Sales Value by Type (2021 VS 2025 VS 2032)
  16. 4.3.2 Global Analgesic and Anti-inflammatory API Sales Value by Type (2021-2032)
  17. 4.3.3 Global Analgesic and Anti-inflammatory API Sales Value Share by Type (2021-2032)
5 Analgesic and Anti-inflammatory API Market by Application
  1. 5.1 Analgesic and Anti-inflammatory API Application Introduction
  2. 5.1.1 Adults
  3. 5.1.2 Children
  4. 5.2 Global Analgesic and Anti-inflammatory API Sales Volume by Application
  5. 5.2.1 Global Analgesic and Anti-inflammatory API Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Analgesic and Anti-inflammatory API Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Analgesic and Anti-inflammatory API Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Analgesic and Anti-inflammatory API Sales Value by Application
  9. 5.3.1 Global Analgesic and Anti-inflammatory API Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Analgesic and Anti-inflammatory API Sales Value by Application (2021-2032)
  11. 5.3.3 Global Analgesic and Anti-inflammatory API Sales Value Share by Application (2021-2032)
6 Analgesic and Anti-inflammatory API Regional Sales and Value Analysis
  1. 6.1 Global Analgesic and Anti-inflammatory API Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Analgesic and Anti-inflammatory API Sales by Region (2021-2032)
  3. 6.2.1 Global Analgesic and Anti-inflammatory API Sales by Region: 2021-2026
  4. 6.2.2 Global Analgesic and Anti-inflammatory API Sales by Region (2027-2032)
  5. 6.3 Global Analgesic and Anti-inflammatory API Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Analgesic and Anti-inflammatory API Sales Value by Region (2021-2032)
  7. 6.4.1 Global Analgesic and Anti-inflammatory API Sales Value by Region: 2021-2026
  8. 6.4.2 Global Analgesic and Anti-inflammatory API Sales Value by Region (2027-2032)
  9. 6.5 Global Analgesic and Anti-inflammatory API Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Analgesic and Anti-inflammatory API Sales Value (2021-2032)
  12. 6.6.2 North America Analgesic and Anti-inflammatory API Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Analgesic and Anti-inflammatory API Sales Value (2021-2032)
  15. 6.7.2 Europe Analgesic and Anti-inflammatory API Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Analgesic and Anti-inflammatory API Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Analgesic and Anti-inflammatory API Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Analgesic and Anti-inflammatory API Sales Value (2021-2032)
  21. 6.9.2 South America Analgesic and Anti-inflammatory API Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Analgesic and Anti-inflammatory API Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Analgesic and Anti-inflammatory API Sales Value Share by Country, 2025 VS 2032
7 Analgesic and Anti-inflammatory API Country-level Sales and Value Analysis
  1. 7.1 Global Analgesic and Anti-inflammatory API Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Analgesic and Anti-inflammatory API Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Analgesic and Anti-inflammatory API Sales by Country (2021-2032)
  4. 7.3.1 Global Analgesic and Anti-inflammatory API Sales by Country (2021-2026)
  5. 7.3.2 Global Analgesic and Anti-inflammatory API Sales by Country (2027-2032)
  6. 7.4 Global Analgesic and Anti-inflammatory API Sales Value by Country (2021-2032)
  7. 7.4.1 Global Analgesic and Anti-inflammatory API Sales Value by Country (2021-2026)
  8. 7.4.2 Global Analgesic and Anti-inflammatory API Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Analgesic and Anti-inflammatory API Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Analgesic and Anti-inflammatory API Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Analgesic and Anti-inflammatory API Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 IOL
  2. 8.1.1 IOL Company Information
  3. 8.1.2 IOL Business Overview
  4. 8.1.3 IOL Analgesic and Anti-inflammatory API Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 IOL Analgesic and Anti-inflammatory API Product Portfolio
  6. 8.1.5 IOL Recent Developments
  7. 8.2 Granules India Limited
  8. 8.2.1 Granules India Limited Company Information
  9. 8.2.2 Granules India Limited Business Overview
  10. 8.2.3 Granules India Limited Analgesic and Anti-inflammatory API Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Granules India Limited Analgesic and Anti-inflammatory API Product Portfolio
  12. 8.2.5 Granules India Limited Recent Developments
  13. 8.3 Mallinckrodt Pharmaceuticals
  14. 8.3.1 Mallinckrodt Pharmaceuticals Company Information
  15. 8.3.2 Mallinckrodt Pharmaceuticals Business Overview
  16. 8.3.3 Mallinckrodt Pharmaceuticals Analgesic and Anti-inflammatory API Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Mallinckrodt Pharmaceuticals Analgesic and Anti-inflammatory API Product Portfolio
  18. 8.3.5 Mallinckrodt Pharmaceuticals Recent Developments
  19. 8.4 Novacyl
  20. 8.4.1 Novacyl Company Information
  21. 8.4.2 Novacyl Business Overview
  22. 8.4.3 Novacyl Analgesic and Anti-inflammatory API Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novacyl Analgesic and Anti-inflammatory API Product Portfolio
  24. 8.4.5 Novacyl Recent Developments
  25. 8.5 BASF
  26. 8.5.1 BASF Company Information
  27. 8.5.2 BASF Business Overview
  28. 8.5.3 BASF Analgesic and Anti-inflammatory API Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 BASF Analgesic and Anti-inflammatory API Product Portfolio
  30. 8.5.5 BASF Recent Developments
  31. 8.6 Hubei Biocause Group
  32. 8.6.1 Hubei Biocause Group Company Information
  33. 8.6.2 Hubei Biocause Group Business Overview
  34. 8.6.3 Hubei Biocause Group Analgesic and Anti-inflammatory API Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Hubei Biocause Group Analgesic and Anti-inflammatory API Product Portfolio
  36. 8.6.5 Hubei Biocause Group Recent Developments
  37. 8.7 BBCA Group
  38. 8.7.1 BBCA Group Company Information
  39. 8.7.2 BBCA Group Business Overview
  40. 8.7.3 BBCA Group Analgesic and Anti-inflammatory API Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 BBCA Group Analgesic and Anti-inflammatory API Product Portfolio
  42. 8.7.5 BBCA Group Recent Developments
  43. 8.8 Hebei Jiheng Pharmaceutical
  44. 8.8.1 Hebei Jiheng Pharmaceutical Company Information
  45. 8.8.2 Hebei Jiheng Pharmaceutical Business Overview
  46. 8.8.3 Hebei Jiheng Pharmaceutical Analgesic and Anti-inflammatory API Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Hebei Jiheng Pharmaceutical Analgesic and Anti-inflammatory API Product Portfolio
  48. 8.8.5 Hebei Jiheng Pharmaceutical Recent Developments
  49. 8.9 Hunan Zhongnan Pharmaceutical
  50. 8.9.1 Hunan Zhongnan Pharmaceutical Company Information
  51. 8.9.2 Hunan Zhongnan Pharmaceutical Business Overview
  52. 8.9.3 Hunan Zhongnan Pharmaceutical Analgesic and Anti-inflammatory API Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Hunan Zhongnan Pharmaceutical Analgesic and Anti-inflammatory API Product Portfolio
  54. 8.9.5 Hunan Zhongnan Pharmaceutical Recent Developments
  55. 8.10 Hebei Jingye Medical Technology
  56. 8.10.1 Hebei Jingye Medical Technology Company Information
  57. 8.10.2 Hebei Jingye Medical Technology Business Overview
  58. 8.10.3 Hebei Jingye Medical Technology Analgesic and Anti-inflammatory API Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Hebei Jingye Medical Technology Analgesic and Anti-inflammatory API Product Portfolio
  60. 8.10.5 Hebei Jingye Medical Technology Recent Developments
  61. 8.11 Anqiu Lu'an Pharmaceutical
  62. 8.11.1 Anqiu Lu'an Pharmaceutical Company Information
  63. 8.11.2 Anqiu Lu'an Pharmaceutical Business Overview
  64. 8.11.3 Anqiu Lu'an Pharmaceutical Analgesic and Anti-inflammatory API Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Anqiu Lu'an Pharmaceutical Analgesic and Anti-inflammatory API Product Portfolio
  66. 8.11.5 Anqiu Lu'an Pharmaceutical Recent Developments
  67. 8.12 Xinhua Pharm
  68. 8.12.1 Xinhua Pharm Company Information
  69. 8.12.2 Xinhua Pharm Business Overview
  70. 8.12.3 Xinhua Pharm Analgesic and Anti-inflammatory API Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Xinhua Pharm Analgesic and Anti-inflammatory API Product Portfolio
  72. 8.12.5 Xinhua Pharm Recent Developments
  73. 8.13 Zhejiang Kangle Pharmaceutical
  74. 8.13.1 Zhejiang Kangle Pharmaceutical Company Information
  75. 8.13.2 Zhejiang Kangle Pharmaceutical Business Overview
  76. 8.13.3 Zhejiang Kangle Pharmaceutical Analgesic and Anti-inflammatory API Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Zhejiang Kangle Pharmaceutical Analgesic and Anti-inflammatory API Product Portfolio
  78. 8.13.5 Zhejiang Kangle Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Analgesic and Anti-inflammatory API Value Chain Analysis
  2. 9.1.1 Analgesic and Anti-inflammatory API Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Analgesic and Anti-inflammatory API Sales Mode & Process
  6. 9.2 Analgesic and Anti-inflammatory API Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Analgesic and Anti-inflammatory API Distributors
  9. 9.2.3 Analgesic and Anti-inflammatory API Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst